|
Abstract To explore benaglutide for treating obese patients with polycystic ovary syndrome (PCOS) and diabetes on their levels of insulin-like growth factor binding protein 3 (IGFBP-3) and microRNA-155 (mir-155). Methods: 78 obese patients with PCOS and type 2 diabetes were selected as the research objects from January 2018 to March 2021. The levels of fasting blood glucose (FPG), glycosylated hemoglobin, fasting insulin (FIns), luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone(T), and the values of insulin resistance index (HOMA-IR), body quality index (BMI) and other indexes of the patients were collected before and after treatment. Real-time fluorescent quantitative PCR method was used to detect the level of serum mir-155 of the patients before and after treatment, enzyme-linked immunosorbent assay was used to determine the level of serum IGFBP-3 of the patients before and after treatment. Pearson method was used to analyze the correlation between the levels of mir-155 and IGFBP-3 of the patients and their levels of metabolic indexes. Results: Compared with those of the patients before treatment, the levels of serum FPG, HBA1C, FIns, LH, T, and Mir-155, and the values of HOMA-IR and BMI of the patients had decreased significantly after treatment, while the levels of IGFBP-3 of the patients had increased significantly (P<0.05). After treatment, the serum Mir-155 level of the patients was positively correlated with their values of HOMA-IR and BMI, and the levels of HBA1C, Fins, and FPG. After treatment, the IGFBP-3 level of the patients was negatively correlated with their values of HOMA-IR and BMI, and the levels of HBA1C, Fins, and FPG. The serum Mir-155 level of the patients was negatively correlated with their IGFBP-3 level (all P<0.05). Conclusion: Benaglutide used for treating the obese patients with PCOS and diabetes can decrease their serum mir-155level and can increase their IGFBP-3 level, so mir-155 and IGFBP-3 may become the bio-targeted treatment sites of the obese patients with PCOS and diabetes.
|
|
|
|
|
|
